Dear Sir,

Cancer patients are at an increased risk of the blood stream infections (BSI) due to their immune-compromised status, repeated hospitalizations, and various procedures. *Staphylococci*, particularly coagulase negative *Staphylococci* (CoNS) are noteworthy pathogens in such cases, and the emergence of multi-drug resistance in *Staphylococci* is a cause of concern. This study was prospectively conducted over a period of 8 months at a cancer institute located in North India to know the prevalence and antimicrobial susceptibility pattern of *Staphylococci* causing BSIs.

All blood culture samples received from patients suspected of having BSI were incubated in BacT/Alert 3D system (BioMe'rieux, Durham, North Carolina/USA). Subcultures were performed from the bottles flagged as positive. Identification and antibiotic susceptibility of the Gram-positive cocci isolated were carried out in VITEK 2-Compact^©^ system (BioMe'rieux, North Carolina/USA) using GP-ID and AST-P628 cards respectively. The resistance patterns of all *Staphylococci* identified as pathogens were analyzed.

Out of total 512 blood samples received, 157 (30.7%) were flagged as positive. Totally, 77 out of 157 (49%) grew Gram-positive organisms, 39 (24.8%) grew Gram-negative organisms and one grew *Candida albicans* on subculture.

*Staphylococci* accounted for 96.1% (74/77) of all Gram-positive isolates with five *Staphylococcus aureus* and 69 CoNS spp. isolates \[[Table 1](#T1){ref-type="table"}\]. There were 2.6% (2/77) isolates of *Enterococcus faecalis* and 1.3% (1/77) isolates of *Kocuria kristinae*.

###### 

Details of the *Staphylococci* isolated from BSI
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All isolates of *S. aureus* were resistant to penicillin and were beta lactamase positive, all of them were methicillin sensitive. About 86.9% of CoNS were resistant to penicillin and 15.9% were β-lactamase positive. Methicillin resistance varied with species of CoNS as shown in [Figure 1](#F1){ref-type="fig"}. Average resistance to methicillin was 71% in all CoNS isolates, which is much higher than previously reported.\[[@ref1]\]
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Resistance of the *Staphylococcal* isolates to other antibiotics is shown in [Table 2](#T2){ref-type="table"}. All isolates of *S. aureus* were resistant to ciprofloxacin while none were resistant to clindamycin, vancomycin, linezolid, tigecycline and daptomycin. 23.2% of the CoNS isolates were resistant to clindamycin (11.6% inducibly resistant and 11.6% inherently resistant). Four (5.8%) isolates of CoNS were intermediately sensitive to teicoplanin while one (1.4%) was completely resistant. Reduced susceptibility of CoNS from BSIs to glycopeptides has been previously reported by Silvia *et al.*\[[@ref2]\] All the CoNS isolates were sensitive to vancomycin, linezolid, tigecycline, and daptomycin.

###### 

Antibiotic resistance pattern (%) of *Staphylococci* in BSIs
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Out of 74 patients who had *Staphylococcal* bacteremia, 13 patients had a fatal outcome (Crude mortality rate = 17.6%). Two of the patients who expired had hematological cancer while the rest 11 patients suffered from solid cancers, and two patients had neutropenia.\[[@ref3]\]

This study shows that *Staphylococci*, particularly CoNS are responsible for a significant number of BSIs in cancer patients. In the present study, *Staphylococcus hominis* (60.8%) was the most common *Staphylococcal* isolate followed by *Staphylococcus hemolyticus* (12.2%) and *Staphylococcus epidermidis* (10.8%). High level of methicillin resistance and resistance to first and second-line antibiotics was seen. Reducing susceptibility to teicoplanin was also observed. Susceptibility was maintained to the life-saving antimicrobials like vancomycin, linezolid, and tigecycline.

To conclude, CoNS are important pathogens causing BSI in cancer patients. The high level of methicillin and multidrug resistance and reducing susceptibility to teicoplanin are causes of concern as they further narrow down the therapeutic options in already difficult to treat BSIs in such patients due to their immune-compromised status.
